Abstract: The present invention relates to nanoparticles and their use to form nanocomposite material, in particular bionanocomposite material, specifically wherein the nanoparticles are formed using plant virus attached to a scaffold of cellulosic material and/or cellulose derived materials, in particular wherein said cellulosic material further comprises plant cell components, for example hemicellulose, pectin, protein or combinations thereof.

Abstract: The present invention relates to nanoparticles and their use to form nanocomposite material, in particular bionanocomposite material, specifically wherein the nanoparticles are formed using plant virus attached to a scaffold of cellulosic material and/or cellulose derived materials, in particular wherein said cellulosic material further comprises plant cell components, for example hemicellulose, pectin, protein or combinations thereof.

Abstract: There is described a process for production of metal-coated virus particles or metallic nanoparticles, said process comprising admixing virus particles with plant material with reducing power and a metal salt, wherein the process can be provided in planta or ex planta and the virus particles aid the production of the metal-coated virus particles or metallic nanoparticles.

Abstract: There is described a process for production of metal-coated virus particles or metallic nanoparticles, said process comprising admixing virus particles with plant material with reducing power and a metal salt, wherein the process can be provided in planta or ex planta and the virus particles aid the production of the metal-coated virus particles or metallic nanoparticles.

Abstract: There is provided a method of inhibiting gene expression by locating a 5?-5 donor splicing site sequence in the 3? UTR of a gene or within coding sequence containing the stop codon of a gene. Stability of homologous mRNA in trans is also adversely affected leading to a reduction in expression. A polynucleotide containing a 5?-donor splicing site sequence in either coding sequence containing the stop codon or the 3? UTR is also provided and in one embodiment is in the form of a vector. The 5?-donor splicing site sequence can be present in multiple copies, for example as a tandem repeat. In one embodiment the 5-donor splicing site sequence has the sequence 5?-MAGGTRAGTA-3? where M is A or C and R is A or G.

Abstract: A method is disclosed for treating an ischemic condition. The method comprises coadministering topically and internally a vasodilator to a patient having the condition for treating the condition.

Abstract: A method is disclosed for treating an ischemic condition. The method comprises coadministering topically and internally a vasodilator to a patient having the condition for treating said condition.

Abstract: A method is disclosed for treating an ischemic condition. The method comprises coadministering topically and internally a vasodilator to a patient having the condition for treating said condition.

Abstract: A method is disclosed for treating an ischemic condition. The method comprises coadministering topically and internally a vasodilator to a patient having the condition for treating said condition.

Abstract: Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 .mu.g/cm.sup.2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 .mu.g/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.